Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Identification of 11-dh-TXB2 in the blood and urine
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers.
Detailed Description
OBJECTIVES: * To identify a potential novel marker of prostate cancer in the blood and urine, 11-dh-TXB2, to be used as a screening tool for prostate cancer as well as in detection of early relapse in patients previously treated for early-stage prostate cancer. OUTLINE: Blood and urine samples are collected and analyzed for plasma and urinary 11-dh-TXB2 levels by HPLC and tandem-mass spectrometry.
Investigators
Elisabeth Heath
Principal Investigator
Barbara Ann Karmanos Cancer Institute
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Identification of 11-dh-TXB2 in the blood and urine
Time Frame: 2 to 4 months